|
| 宝石CT的骨密度测量应用于内分泌治疗乳腺癌患者骨质疏松程度评价的可行性研究 |
| The feasibility study of measuring bone mineral density using spectral CT in the evaluation of osteoporosis in patients with breast cancer after endocrinal therapy |
| 投稿时间：2013-01-22 |
| DOI： |
| 中文关键词: 宝石CT DEXA 骨密度 骨质疏松 乳腺癌 |
| 英文关键词:Spectral CT DEXA BMD Osteoporosis Breast cancer |
| 基金项目: |
|
| 摘要点击次数: 978 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨宝石CT骨密度(BMD)测量技术对内分泌治疗后乳腺癌患者骨质疏松程度评价的可行性.方法 采用宝石CT骨密度测量技术和双能X线骨密度仪(DEXA),对23例内分泌治疗前及治疗半年后乳腺癌患者分别进行骨密度测量,测量部位为腰2椎体,分别比较两种方法在内分泌治疗前及治疗半年后乳腺癌患者的BMD变化,来判定骨质疏松程度,并比较两种方法的一致性,统计学方法用t检验比较组内差异(P＜0.05),用方差分析比较组间差异(P＞0.05).结果 所有病人经过6个月的治疗,骨密度均有不同程度下降.宝石CT测量治疗前后BMD平均值分别为43.72±18.31 mg/ml、37.18±18.42 mg/ml,明显降低;DEXA测量治疗前后BMD值分别为0.807±0.113 g/cm2、0.76±0.099 g/cm2.两种方法对治疗前后骨密度测量具有一致性(P＞0.05).结论 乳腺癌内分泌治疗半年即可引起患者骨质疏松,宝石CT骨密度测量技术对监测内分泌治疗患者的骨密度变化是一种简单且可行的方法. |
| 英文摘要: |
| Objective To assess the feasibility of measuring bone mineral density (BMD) using Gemstone Spectral Imaging (GSI) with spectral CT (Discovery CT 750HD, GE) in patients with breast cancer after endocrinal therapy. Methods Twenty-three patients with breast cancer were included in this study. BMD of the 2nd lumbar vertebra in all patients were measured using both spectral CT and dual-energy X ray absorptiometry (DEXA) before and half-a-year after endocrinal therapy. The changes of BMD were compared, in order to evaluate the degree of osteoporosis and the consistency of both methods. Variance between the two groups was analyzed using T test method. Results BMD of each patient decreased after the 6-month endocrinal therapy. BMD measured using spectral CT before and after the therapy was 43.72±18.31mg/ml and 37.18±18.42mg/ml, respectively, which had a significant decrease after the therapy. BMD measured using DEXA before and after the therapy was 0.807±0.113 g/cm2 and 0.76±0.099g/cm2, respectively. Consistency of both methods was observed in measuring BMD before and after the therapy (P＞0.05). Conclusion After half-a-year endocrinal therapy, patients with breast cancer can develop osteoporosis. The measurement of BMD using spectral CT is a simple and feasible way to monitor the changes of BMD in breast cancer patients receiving endocrinal therapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|